Loading…

Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

We evaluated hemostatic markers in patients who underwent major orthopedic surgery, including total hip and total knee arthroplasty, and were treated for the prophylaxis of deep vein thrombosis (DVT) with or without fondaparinux (anti-Xa group, n  = 98 and without anti-Xa group, n  = 20). The freque...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2012-02, Vol.95 (2), p.160-166
Main Authors: Yoshida, Kakunoshin, Wada, Hideo, Hasegawa, Masahiro, Wakabayashi, Hiroki, Matsumoto, Takeshi, Shimokariya, Yuji, Noma, Katsura, Yamada, Norikazu, Uchida, Atsumasa, Nobori, Tsutomu, Sudo, Akihiro
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated hemostatic markers in patients who underwent major orthopedic surgery, including total hip and total knee arthroplasty, and were treated for the prophylaxis of deep vein thrombosis (DVT) with or without fondaparinux (anti-Xa group, n  = 98 and without anti-Xa group, n  = 20). The frequency of DVT was significantly higher in the without anti-Xa group than in the anti-Xa group, but the reduction of hemoglobin and fibrinolytic marker levels was significantly lower in the without anti-Xa group than in the anti-Xa group. Eighteen patients in the anti-Xa group showed a reduction in hemoglobin of more than 2 g/dl, and those individuals were considered to be the increased bleeding (IB) group. The concentration of fibrinolytic markers in the anti-Xa group was significantly higher in the IB group than in the non-IB group. There were also no significant differences in the levels of anti-Xa activity, plasminogen activator inhibitor-I, soluble fibrin and antithrombin between the IB and non-IB groups. In conclusion, elevated fibrinolysis induced by increased bleeding may lead to further increases in bleeding in patients receiving thromboprophylaxis with fondaparinux following major orthopedic surgery.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-012-1004-2